CMG2 Expression Is an Independent Prognostic Factor for Soft Tissue Sarcoma Patients

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Capillary morphogenesis gene 2 (CMG2), also known as anthrax toxin receptor 2 (ANTXR2), is a transmembrane protein involved in extracellular matrix adhesion and tissue remodeling.
• CMG2 influences endothelial cell proliferation and angiogenesis, and its reduced expression correlates with poorer survival in breast carcinoma patients.

Purpose of the Study:

• To investigate the expression of CMG2 mRNA and protein in soft tissue sarcoma (STS).
• To determine the association between CMG2 expression levels and patient outcomes in STS.

Main Methods:

• Quantitative real-time PCR was used to measure CMG2 mRNA in 121 STS tumor samples.
• Enzyme-linked immunosorbent assay (ELISA) was employed to quantify CMG2 protein in 52 STS tumor samples.
• Kaplan-Meier analysis was performed to assess the correlation between CMG2 expression and disease-specific survival.

Main Results:

• A significant positive correlation was observed between CMG2 mRNA and protein expression (r _s = 0.31; p = 0.027).
• CMG2 mRNA expression correlated with genes involved in extracellular matrix remodeling, including CD26 and the uPA system.
• Low CMG2 mRNA expression was significantly associated with worsened disease-specific survival (25 vs. 96 months; p = 0.013), particularly in high-stage tumors.

Conclusions:

• Decreased CMG2 expression serves as a negative prognostic factor in soft tissue sarcoma.
• CMG2 represents a potential candidate for further research into the mechanisms of STS development and progression.